MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types

MOTIVATION The data gathered by the Pan-Cancer initiative has created an unprecedented opportunity for illuminating common features across different cancer types. However, separating tissue-specific features from across cancer signatures has proven to be challenging. One of the often-observed properties of the mutational landscape of cancer is the mutual exclusivity of cancer driving mutations. Even though studies based on individual cancer types suggested that mutually exclusive pairs often share the same functional pathway, the relationship between across cancer mutual exclusivity and functional connectivity has not been previously investigated. RESULTS We introduce a classification of mutual exclusivity into three basic classes: within tissue type exclusivity, across tissue type exclusivity and between tissue type exclusivity. We then combined across-cancer mutual exclusivity with interactions data to uncover pan-cancer dysregulated pathways. Our new method, Mutual Exclusivity Module Cover (MEMCover) not only identified previously known Pan-Cancer dysregulated subnetworks but also novel subnetworks whose across cancer role has not been appreciated well before. In addition, we demonstrate the existence of mutual exclusivity hubs, putatively corresponding to cancer drivers with strong growth advantages. Finally, we show that while mutually exclusive pairs within or across cancer types are predominantly functionally interacting, the pairs in between cancer mutual exclusivity class are more often disconnected in functional networks.

[1]  J. Horsfield,et al.  Gene Regulation by Cohesin in Cancer: Is the Ring an Unexpected Party to Proliferation? , 2011, Molecular Cancer Research.

[2]  Eli Upfal,et al.  Discovery of Mutated Subnetworks Associated with Clinical Data in Cancer , 2011, Pacific Symposium on Biocomputing.

[3]  M. Newman,et al.  On the uniform generation of random graphs with prescribed degree sequences , 2003, cond-mat/0312028.

[4]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[5]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[6]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[7]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[8]  Teresa M. Przytycka,et al.  Chapter 5: Network Biology Approach to Complex Diseases , 2012, PLoS Comput. Biol..

[9]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[10]  Eli Upfal,et al.  Algorithms for Detecting Significantly Mutated Pathways in Cancer , 2010, RECOMB.

[11]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[12]  Niko Beerenwinkel,et al.  Modeling Mutual Exclusivity of Cancer Mutations , 2014, RECOMB.

[13]  Julie M. Sahalie,et al.  Supplementary Figure and Table Legends , 2022 .

[14]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[15]  Nam Jin Yoo,et al.  Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors , 2013, International journal of cancer.

[16]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[17]  Peifang Liu,et al.  Functional SNP in the microRNA-367 binding site in the 3′UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification , 2011, Proceedings of the National Academy of Sciences.

[18]  Chris Sander,et al.  Using MEMo to Discover Mutual Exclusivity Modules in Cancer , 2013, Current protocols in bioinformatics.

[19]  Masao Nagasaki,et al.  Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms , 2012, Nature Genetics.

[20]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[21]  Benjamin J. Raphael,et al.  De novo discovery of mutated driver pathways in cancer , 2011 .

[22]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[23]  Teresa M. Przytycka,et al.  Module Cover - A New Approach to Genotype-Phenotype Studies , 2012, Pacific Symposium on Biocomputing.

[24]  Roded Sharan,et al.  Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..

[25]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[26]  Haiyuan Yu,et al.  HINT: High-quality protein interactomes and their applications in understanding human disease , 2012, BMC Systems Biology.

[27]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.